Delores L. Galias, RN, RHIT
STATEMENT OF CONFIDENTIALITY:
The information contained in this electronic message and any attachments to this message are intended for the exclusive use of the addressee(s) and may contain confidential or privileged information. If you are not the intended recipient, please notify D. Galias, RN, RHIT immediately at [EMAIL PROTECTED] and destroy all copies of this message and any attachments. Thank you for your cooperation
--- Begin Message ---Item Type: Appointment Start Date: 04/20/2004 02:00 pm Eastern Daylight Time (Tuesday) Duration: 2 Hours Place: CMS Auditorium (Baltimore)Schedule Change and New Open Door Forum Announcement: DATE: April 20, 2004 � Special Listening Session on MMA Section 303(d): (Competitive Bidding for Part B Drug Distribution beginning in 2006) TIME CHANGE: Will now be condensed to only one hour in length, from 2:00PM to 3:00PM (EST). The second hour, (from 3:00PM to 4:00PM) will be modified as follows: ADDED FORUM Topic: � A Special Open Door Forum will run from 3:00PM to 4:00PM to allow CMS to provide an interactive Question and Answer period related to Manufacturer Submission of Average Sales Price data for Medicare Part B Drugs. This is a follow-up to concerns raised after having a previous Open Door Forum Listening Session on March 2, 2004 and prior to having published the recent Interim Final Rule with comment period in the Federal Register on April 6, 2004. The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA) included several important provisions related to drug coverage and payment in the Medicare program. One of the provisions establishes a new Average Sales Price (ASP) payment system beginning in 2005 for Medicare Part B covered outpatient drugs and biologicals not paid on a cost or prospective payment system basis, including drugs furnished incident to a physician's service, drugs furnished under the durable medical equipment (DME) benefit, certain oral anti-cancer drugs, and oral immunosuppressive drugs. Section 303 of the MMA requires manufacturers of these drugs and biologicals to submit quarterly ASP data to the Centers for Medicare and Medicaid Services (CMS) beginning April 30, 2004. CMS recently published an Interim Final Regulation with Comment "Manufacturer Submission of Manufacturer's Average Sales Price (ASP) Data for Medicare Part B Drugs and Biologicals" and is interested in holding this Special Open Door Forum Session to answer questions related to the submission of ASP data by manufacturers and to allow interested parties to hear and be heard by other members of the healthcare industry. If necessary, we will post additional information regarding this Special Listening Session on the following website: http://www.cms.hhs.gov/providers/drugs/default.asp. Questions may be sent in advance to [EMAIL PROTECTED] Participation instructions: There are 2 ways to participate in both of these Open Door Forum Sessions, by phone or in-person. To participate in-person at the CMS Baltimore Site, an RSVP is required. To register, please RSVP (by close of business Thursday April 15, 2004) via email to [EMAIL PROTECTED] if you plan to attend. Please include the word "Registration" in the subject line of your message, send us your name along with the name of your organization, and contact information, and indicate whether or not you plan to speak. Please arrive no later than 1:30 PM. Photo identification is required at security points. ADDRESS: CMS Single Site Building Auditorium 7500 Security Boulevard Baltimore, MD 21244 Map & Directions: http://cmsnet.cms.hhs.gov/hpages/ocsq/cmsdirections-north.htm To participate by phone: Dial: 1-800-837-1935 � Reference Conference ID: 6330178 if you plan to only dial in for the first hour (at 2:00PM) regarding MMA Section 303(d) Competitive Bidding for Part B Drugs in 2006 � Also use Conference ID 6330178 if you plan to attend both sessions for the full two-hour period. (There will be no need to hang up and re-dial in again.) � Reference Conference ID: 6655670 if you plan to only dial in for the 3:00PM Question and Answer Session on Submission of Manufacturer ASP Data for Part B Drugs. Note: TTY Communications Relay Services are available for the Hearing Impaired. For TTY services dial 7-1-1 or 1-800-855-2880 and for Internet Relay services click here http://www.consumer.att.com/relay/which/index.html . A Relay Communications Assistant will help. � ENCORE Telephone Replay: 1-800-642-1687; Conf. ID# 6330178 for the Special Listening Session on MMA Section 303(d): (Competitive Bidding for Part B Drug Distribution beginning in 2006) � ENCORE Telephone Replay: 1-800-642-1687; Conf. ID# 6655670 for the Question and Answer Session on Submission of Manufacturer ASP Data for Part B Drugs. "Encore" is a recording of this call that can be accessed by dialing 1-800-642-1687 and entering the Conf. ID beginning 2 hours after the call has ended. The recording expires after 4 full days. For Forum Schedule updates, Listserv registration and Frequently Asked Questions please visit our website at www.cms.hhs.gov/opendoor/ Thank you.
--- End Message ---
